GERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, ...
The next-generation CGM is now available in Sweden, with launches expected in Germany, Spain and Italy during the coming weeks as part of a ...
GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable ...
GERMANTOWN, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable ...
MANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and ...
At long last, Eversense, the implantable continuous glucose monitoring system from Senseonics, has received FDA clearance to be marketed in the United States. “The FDA is committed to advancing novel ...
MANCHESTER, N.H. and GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, and Senseonics Holdings, Inc. (NYSE ...
The US Food and Drug Administration (FDA) announced late Thursday expanded and new approvals of two diabetes management devices—Medtronic’s MiniMed 670G hybrid closed looped system and Senseonics’ ...
The US Food and Drug Administration (FDA) has approved the first-ever implantable continuous glucose monitoring system, the Eversense CGM (Senseonics), for people aged 18 years and older with diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results